DEVELOPMENT OF VACCINES AGAINST PAPILLOMAVIRUSES

乳头瘤病毒疫苗的开发

• 批准号: 2098640
• 负责人: FELIX O WETTSTEIN
• 金额: $ 10.27万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-08-20 至 1995-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2098640
• 关键词: Baculoviridae; Listeria; cutaneous papilloma; cytotoxic T lymphocyte; enzyme linked immunosorbent assay; epitope mapping; humoral immunity; immunization; laboratory rabbit; lymphocyte proliferation; oncogenic virus; rabbit papillomavirus; recombinant DNA; southern blotting; structural genes; vaccinia virus; viral vaccines; virus antigen; virus protein; virus replication; western blottings

Cervical cancer is one of the most common cancers in women worldwide and it is believed that a small number of genital human papillomaviruses play an essential role in the development of these cancers. Development of vaccines to protect from infection or effective in therapy of lesions could greatly reduce morbidity and mortality caused by these viruses. Because of the narrow host range of papillomaviruses, it is not possible to develop a animal model with the human viruses. Our goal is to use cottontail rabbit papillomavirus (CRPV) as an animal model to test strategies for protective and therapeutic vaccine development. CRPV, as some of the human viruses, is associated with the development of cancers. The specific aims are: 1) Develop a unique novel system for vaccines based on the used Listeria monocytogenes and test it in the CRPV system. 2) Construct recombinant vaccinia viruses expressing both viral structural genes for optimal maintenance of conformational epitopes and expressing viral protein and IL2 for increased T cell stimulation. 3) Express viral structural proteins with recombinant bacuolovirus or in yeast for subunit vaccine development. 4) Evaluate the possibility to develop a peptide vaccine.

子宫颈癌是全世界妇女中最常见的癌症之一